Regeneron Scales Up Manufacturing of COVID-19 Antibody Cocktail

Regeneron said it will produce hundreds of thousands of doses of its potential COVID-19 antibody treatment REGN-COV2 by the end of August.

The company expects to begin clinical studies of the antibody “cocktail” therapy next month.

Regeneron is also conducting a phase 2/3 trial with Sanofi to evaluate its rheumatoid arthritis treatment Kevzara (sarilumab) for treating severe COVID-19 infections.